Gene Therapy


  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    PTC's first gene therapy gains European regulator's backing

    The brain-infused treatment for a rare neurological disease would be one of only three gene therapies commercially available in the EU. PTC plans to ask for FDA approval later this year.

    By May 20, 2022
  • Image attribution tooltip
    Danielle Ternes/BioPharma Dive

    Scientists home in on cause of Duchenne gene therapy side effect

    An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.

    By Updated May 18, 2022
  • Trendline

    Gene Therapy

    Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges. 

    By BioPharma Dive staff
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Ultragenyx strikes deal with struggling Abeona for rare disease gene therapy

    The treatment, which is designed to treat Sanfilippo syndrome, could become Ultragenyx's first gene therapy to reach market in the U.S., according to the biotech's CEO.

    By May 17, 2022
  • Image attribution tooltip
    libre de droit via Getty Images

    Pfizer cleared to restart hemophilia gene therapy trial

    While a voluntary pause in dosing new patients will remain in place, the FDA's decision puts the study back on track to deliver data in 2023.

    By May 3, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    After setbacks, a gene therapy company mulls a sale

    Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.

    By April 28, 2022
  • Image attribution tooltip
    The image by Pixabay is licensed under CC BY 1.0

    FDA clears Pfizer to restart Duchenne gene therapy trial, with new safeguards

    The regulator has asked Pfizer to closely monitor patients in a hospital setting for a week as part of a deal to end a study suspension that's lasted more than four months.

    By April 28, 2022
  • Image attribution tooltip
    libre de droit via Getty Images

    Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce

    The company is the latest in a growing list of gene therapy developers to restructure and cut jobs during an industry-wide downturn. 

    By April 27, 2022
  • Image attribution tooltip
    DKosig via Getty Images

    Undeterred by gene therapy's struggles, a startup launches into a downturn

    Apertura Gene Therapy, a new company formed by Deerfield, is hoping a suite of next-generation tools will help it stand out at a time when this area of research has fallen out of favor with some public investors.

    By April 26, 2022
  • Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Nkarta gives first look at two 'natural killer' cell therapies for blood cancer

    The results build on early evidence that NK cell treatments may become viable medicines for leukemia and lymphoma, while it's still unclear whether they're as effective, or last as long, as T cell therapies. 

    By April 25, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Regeneron, in search of an eye gene therapy, turns to a young biotech

    Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.

    By April 6, 2022
  • Image attribution tooltip
    Novartis

    FDA clears second Novartis plant for gene therapy manufacturing

    The 170,000-square-foot plant located in North Carolina can now fulfill its primary function: producing commercial-grade Zolgensma, which has become one of the Swiss pharma's top-selling drugs.

    By April 5, 2022
  • Bluebird, after warning of dwindling cash, to lay off 30% of workforce

    The restructuring will result in job cuts across the company, a spokesperson said, as Bluebird awaits regulatory decisions on two of its products. 

    By April 5, 2022
  • Image attribution tooltip

    Pogonici/Stock.adobe.com

    Sponsored by SGS

    Viral vector design for gene therapies

    Safety issues in clinical trials cast doubt on the ability of gene therapy to safely mitigate disease, prompting further research into understanding the virus-host interaction that resulted in new generations of viral vectors.

    By Robert Cartee, Ph.D., Senior Director Biopharmaceutical Services • April 4, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Yet another gene therapy developer turns to layoffs

    Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.

    By April 1, 2022
  • Image attribution tooltip
    Permission granted by Biogen
    ALS drug development

    Biogen shelves ALS drug after early-stage trial failure

    The study setback raises questions over how well a type of genetic medicine can work in adults with central nervous system disorders like ALS.

    By March 28, 2022
  • Image attribution tooltip
    Dr_Microbe via Getty Images

    As biotech retreats, gene therapy companies retrench and redraw plans

    At least nine biotechs working in cell or gene therapy have announced layoffs, cost cuts or restructured their research since December — restructurings that have coincided with a stock market downturn.

    By March 24, 2022
  • Image attribution tooltip
    Courtesy of Business Wire

    Al Sandrock takes on CEO role at gene therapy developer

    The well-known researcher and Biogen alumnus has agreed to take the top spot at Voyager Therapeutics, which, last spring, underwent a "strategic shift" that saw its then-CEO and research head depart.

    By March 22, 2022
  • Image attribution tooltip
    Courtesy of Scribe Therapeutics

    CRISPR pioneer's biotech taps ex-Barclays banker as CFO

    In an interview, David Parrot walked through some of the challenges he faces preparing gene editing biotech Scribe Therapeutics for an IPO during a sector-wide downturn.

    By Maura Webber Sadovi • March 21, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    FDA sets out advice to developers of gene editing medicines

    Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing.

    By March 16, 2022
  • Passage Bio to cut jobs in latest biotech restructuring

    Stung by a stock market downturn, a number of biotechs are trimming spending and reprioritizing research to save cash. Passage's layoffs will reduce its workforce by 13%.

    By March 15, 2022
  • Image attribution tooltip
    Novartis

    Novartis turns cell therapy skill into contract manufacturing deal

    In an unusual arrangement, the Swiss pharma will make Carisma Therapeutics' experimental cell therapy at its Morris Plains factory, part of its plans to build up a CMO business.

    By March 10, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Novartis turns to Voyager for nervous system gene therapies

    The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager's capsids, which would be used to develop gene therapies for the central nervous system.

    By March 8, 2022
  • Image attribution tooltip
    Meletios Verras via Getty Images
    CRISPR gene editing

    Gene editing biotechs face new uncertainty after CRISPR patent ruling

    A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.

    By March 2, 2022
  • Image attribution tooltip
    Permission granted by Intellia Therapeutics
    CRISPR gene editing

    Intellia presses forward with new results for pioneering CRISPR drug

    The findings build on early evidence that gene editing inside the body could safely and effectively treat disease, and suggest the effects of Intellia's medicine might last. 

    By Updated Feb. 28, 2022
  • Image attribution tooltip
    Amicus Therapeutics

    Amicus' SPAC deal unravels, leading to layoffs and cost cuts

    The biotech is calling off plans to spin out its gene therapy business via a merger with a blank check company, citing unfavorable market conditions and a "challenging environment."

    By Kristin Jensen • Feb. 24, 2022